About ILUMYA®
ILUMYA (tildrakizumab-asmn) is a humanized lgG1/k monoclonal antibody designed to selectively bind to the p19 subunit of interleukin-23 (IL-23) and inhibit its interaction with the IL-23 receptor, leading to inhibition of the release of pro-inflammatory cytokines and chemokines. ILUMYA is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, in the United States. ILUMYA has also been approved for moderate-to-severe plaque psoriasis in Australia and Japan, and under the brand name ILUMETRI® in Europe.
Videos
About Sun Dermatology
Sun Dermatology (the branded dermatology division of Sun Pharmaceutical Industries, Inc. in the United States) is committed to expanding its dermatology portfolio to bring more treatment options and ongoing support for healthcare providers and patients around the world. For more than 30 years, it has been dedicated to advancing the science of dermatology for a variety of conditions like plaque psoriasis, acne, minimally to moderately thick actinic keratoses of the face, scalp or upper extremities, and locally advanced basal cell carcinoma. Sun Pharmaceutical Industries Limited, along with its subsidiaries, is ranked second in dermatology prescription volume within the U.S. per IQVIA and is the fourth largest specialty generic pharmaceutical company globally.
 Avoid use if pregnant. Patients must enroll in iPLEDGE® Program.
See full Prescribing Information, including BOXED WARNING
|
|
|
 During and for a time after treatment, females should avoid pregnancy and males should use condoms.
See full Prescribing Information, including BOXED WARNING
|
|
Avoid use if pregnant. Patients must enroll in iPLEDGE® Program.
See full Prescribing Information, including BOXED WARNING
|
|
During and for a time after treatment, females should avoid pregnancy and males should use condoms.
See full Prescribing Information, including BOXED WARNING
|
|
Avoid use if pregnant. Patients must enroll in iPLEDGE® Program.
See full Prescribing Information, including BOXED WARNING
|
|
|
|
During and for a time after treatment, females should avoid pregnancy and males should use condoms.
See full Prescribing Information, including BOXED WARNING
|
|
Avoid use if pregnant. Patients must enroll in iPLEDGE® Program.
See full Prescribing Information, including BOXED WARNING
|
|
|
During and for a time after treatment, females should avoid pregnancy and males should use condoms.
See full Prescribing Information, including BOXED WARNING
|
|
INDICATION
ILUMYA® (tildrakizumab-asmn) is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
ILUMYA is contraindicated in patients with a previous serious hypersensitivity reaction to tildrakizumab or to any of the excipients.
WARNINGS AND PRECAUTIONS
Hypersensitivity
Cases of angioedema and urticaria occurred in ILUMYA-treated subjects in clinical trials. If a serious allergic reaction occurs, discontinue ILUMYA immediately and initiate appropriate therapy.
Infections
ILUMYA may increase the risk of infection. Treatment with ILUMYA should not be initiated in patients with a clinically important active infection until the infection resolves or is adequatelly treated.
Consider the risks and benefits of treatment prior to prescribing ILUMYA in patients with a chronic infection or a history of recurrent infection. Instruct patients receiving ILUMYA to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and consider discontinuation of ILUMYA until the infection resolves.
Pretreatment Evaluation for Tuberculosis
Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with ILUMYA. Do not administer ILUMYA to patients with active TB infection. Initiate treatment of latent TB prior to administering ILUMYA. Consider anti-TB therapy prior to initiation of ILUMYA in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Patients receiving ILUMYA should be monitored closely for signs and
symptoms of active TB during and after treatment.
Immunizations
Prior to initiating therapy with ILUMYA, consider completion of all age-appropriate immunizations according to current immunization guidelines. Patients treated with ILUMYA should not receive live vaccines.
Adverse Reactions
The most common (>1 %) adverse reactions associated with ILUMYA treatment that were more frequent than in the placebo group are upper respiratory infections, injection-site reactions, and diarrhea.
Please see Full Prescribing Information in the Links and Downloads section above or at ILUMYApro.com.